Crescent Biopharma, Inc. CBIO
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Crescent Biopharma, Inc. (CBIO) is a healthcare company listed in the US with a market value of about $550M. In the twelve months to September 30, 2026 it had revenue of $15M and net income of -$178M, a net margin of -1188.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 1% a year, a 5-year average ROIC of -85%.
About Crescent Biopharma
Crescent Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $15M in 2014 to $11M in 2025, a decline of about 2.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 26% over three years (buybacks). It spends 1273% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $11M | — | $10000 | $75000 | $1M | $10M | — | — | — | $18500 |
| Net income | -$178M | -$154M | -$38M | -$37M | -$47M | -$63M | -$51M | -$58M | -$48M | -$33M | -$32M |
| Free cash flow | -$82M | -$72M | -$31M | -$35M | -$47M | -$58M | -$39M | -$52M | -$43M | -$30M | -$30M |
| EPS (diluted) | $-7.29 | $-3.96 | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | $-1.18 | $-1.13 | $-1.50 |
| Net margin | -1188.3% | -1419.6% | — | -369000.0% | -62251.7% | -5469.0% | -502.1% | — | — | — | -171900.0% |
| ROIC | — | -58.9% | -143.3% | -79.1% | -85.4% | -60.0% | -31.1% | -30.7% | -19.4% | -22.4% | -71.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $32.33, 129% above the current price; targets range from $28.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $-2.76 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Crescent Biopharma pay a dividend?
Not currently.
Is Crescent Biopharma a good stock to buy?
We do not give buy or sell advice. Crescent Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.